Skip to main content
. 2021 Jun 15;11:685515. doi: 10.3389/fonc.2021.685515

Figure 9.

Figure 9

Effects of APC, BRAF and TP53 mutation on immunotherapy efficacy in CC. (A–C) Comparison of survival curves among APC-mutated patients with non-immunotherapy (blue), APC-mutated patients with immunotherapy (red), non-APC-mutated patients with non-immunotherapy (yellow) and, non-APC-mutated patients with immunotherapy (green) by Kaplan–Meier analysis in CC cohort (A), RCC cohort (B) and LCC cohort (C). (D–F) Comparison of survival curves among BRAF-mutated patients with non-immunotherapy (blue), BRAF-mutated patients with immunotherapy (red), non-BRAF-mutated patients with non-immunotherapy (yellow) and, non-BRAF-mutated patients with immunotherapy (green) by Kaplan–Meier analysis in CC cohort (D), RCC cohort (E) and LCC cohort (F). (G–I) Comparison of survival curves among TP53-mutated patients with non-immunotherapy (blue), TP53-mutated patients with immunotherapy (red), non-TP53-mutated patients with non-immunotherapy (yellow) and, non-TP53-mutated patients with immunotherapy (green) by Kaplan–Meier analysis in CC cohort (G), RCC cohort (H) and LCC cohort (I).